Ivermectine Cf

Ivermectin, the active ingredient in Ivermectine Cf, is an anthelmintic presented as a tablet for oral use. It treats parasitic infections such as strongyloidiasis, onchocerciasis, scabies and lymphatic filariasis in appropriate patients by targeting parasite nerve and muscle function.

GNH USA supplies Ivermectine Cf as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality compliance with EU standards and reliable global distribution. The company adheres to stringent manufacturing practices and provides regulatory documentation for importers.

Ivermectin acts on a broad range of parasitic organisms, providing therapeutic benefit in several helminthic and ectoparasitic diseases.

Strongyloidiasis: eradicates intestinal larvae and prevents dissemination Onchocerciasis: reduces microfilarial skin load and ocular involvement Scabies: eliminates mite infestation and relieves skin lesions Lymphatic filariasis: decreases adult worm burden and interrupts transmission Cutaneous larva migrans: resolves creeping skin eruption caused by hookworm larvae

Ivermectin may cause a range of adverse reactions, from mild discomfort to severe systemic events.

Common Side Effects: - Nausea and abdominal discomfort - Diarrhea or loose stools - Dizziness or headache - Mild skin rash

Serious or Rare Side Effects: - Stevens‑Johnson syndrome or other severe cutaneous reactions - Hepatotoxicity with elevated liver enzymes - Neurological events such as seizures, altered consciousness or ataxia - Anaphylactic or severe allergic reactions - Vision disturbances including blurred vision

When prescribing Ivermectine Cf, clinicians should consider several precautionary measures to ensure safe use.

Assess liver function: monitor hepatic enzymes before and during therapy Evaluate for Loa loa infection: avoid in patients with high microfilarial loads due to neurologic risk Review concomitant medications: consider potential pharmacokinetic interactions Use with caution in pregnancy or breastfeeding: only if benefit outweighs risk Monitor for neurologic symptoms: discontinue if severe CNS effects occur Store at ambient temperature: keep in original pack, protect from moisture and light

Ivermectin can interact with other medicines, and some combinations require avoidance while others need careful monitoring.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole) may increase ivermectin exposure - P‑glycoprotein inhibitors (e.g., verapamil) can raise systemic levels - Co‑administration with other neurotoxic antiparasitics (e.g., benzimidazoles) may heighten neurotoxicity risk

Moderate Interactions (Monitor Closely): - Warfarin: possible enhancement of anticoagulant effect, monitor INR - Concurrent antiparasitic agents: dose adjustment may be needed - Certain antihistamines: may increase sedation, observe patient response